Human Bone Marrow Mesenchymal Stem Cells Trans-differentiating into Insulin-producing Cells for the Treatment of Type I Diabetes

• Main Authors: Wei-Cheng Jiang, 蔣偉程
• Other Authors: Tien-Hua Chen
• Format: Others
• Language: zh-TW
• Published: 2008
• Online Access: http://ndltd.ncl.edu.tw/handle/44238061679581635090

碩士 === 國立陽明大學 === 解剖暨細胞生物學研究所 === 96 === AIM: To study the capacity of human bone marrow mesenchymal stem cells (hBM-MSCs) trans-differentiating into insulin-producing cells and to observe the effect of portal vein transplantation of insulin-producing cells in the treatment of streptozotocin-induced diabetic rats. METHODS: Bone marrow mesenchymal stem cells were isolated from human and induced to differentiate into insulin-producing cells under defined conditions. Differentiation was evaluated with RT-PCR, Real time-PCR, Western blot and Immunocytochemistry. C-peptide release after glucose challenge was tested with ELISA. Then heterogeneic insulin-producing cells were transplanted into portal vein of diabetic rats via Port-A. Blood glucose levels were monitored and C-peptide were detected in the liver of the recipient by Immunohistochemistry. RESULTS: hBM-MSCs were spheroid adherent monolayers with high CD44, CD105, CD73 and very low CD34, CD38, CD45 expression. Typical insulin-producing cells expressed C-peptide after induction. Differentiated cells expressed β cells related genes and hormones on Day 3 and Day 13. The C-peptide and insulin detected on Day 13 were high expression. After transplantation, insulin-producing cells could locate in the liver expressing human C-peptide and lower the glucose levels of diabetic rats. CONCLUSION: hBM-MSCs could be trans-differentiated into insulin-producing cells in vitro. Portal vein transplantation of insulin-producing cells could alleviate the hyperglycemia of diabetic rats. Key words：Mesenchyal stem cells、C-peptide、Portal vein